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The tropical disease malaria is responsible for more than 400,000 deaths annually, especially in
Southeast Asia and Africa. Although the number of malaria cases is declining, there still is an urgent need
for novel antimalarial agents. The emergence of hybrid antimalarial agents and the precedence set by the
antimalarial drug ferroquine (FQ) prompted us to design new ferrocene-containing quinoline structures.
Herein, we report the efficient synthesis of three different series of ferrocene-quinoline conjugates and a
class of ferrocene-containing heterotricycles in good to high yields. For all twenty novel ferrocenyl de-
rivatives, electrochemical properties were investigated using cyclic voltammetry and antiplasmodium
evaluation against a chloroquine-susceptible NF54 strain of the human malaria parasite Plasmodium
falciparumwas conducted, pointing to three compounds showing submicromolar potency. Subsequently,
cytotoxicity assays against a Chinese Hamster Ovarian cell line and evaluation against a chloroquine-
resistant strain of Plasmodium falciparum for these three compounds revealed selective and promising
antiplasmodium activity.
© 2019 Elsevier Masson SAS. All rights reserved.1. Introduction
Malaria is a lethal parasitic infection caused by a protozoan
parasitic disease, transmitted by Anopheles mosquitoes. In general,
five species of the genus Plasmodium are known to provoke ma-
larial infections in humans: P. falciparum, P. vivax, P. malariae,
P. ovale and P. knowlesi, but the majority of cases is caused by
Plasmodium falciparum (P. falciparum) and Plasmodium vivax
(P. vivax) [1e5]. The life-threatening parasite P. falciparum is
endemic in South and East Asia, South America, the Caribbean, the
Middle East and Africa, whereas the non-lethal P. vivax prevails innces, University of Pristina,
om (A. Minic), Matthias.
served.Central America, India and parts of the Eastern Mediterranean.
P. ovale and P. malariae are two rather rare, non-lethal parasites,
most commonly found in Africa and Papua New Guinea [2]. Finally,
in certain parts of Southeast Asia, P. knowlesi has been identified
recently to induce a type of monkey malaria [6]. An estimated 219
million malaria cases were reported in 2017, resulting in 435,000
deaths. Especially Africa is affected by malaria, where mortality
rates are highest (61%) in children under the age of five [7]. In
addition, despite intensive investment in the development of a
malaria vaccine, only limited success has been achieved in that
respect [8]. Although several classes of antimalarial drugs are
currently available, issues of toxicity, lower efficiency and resis-
tance development by malaria parasites have reduced their overall
therapeutic efficiency. Consequently, the search for new antima-
larials remains an important challenge in drug discovery.
The use of metals to induce/enhance cytotoxicity of bioactive
compounds has increased since the emergence of platinum-based
A. Minic et al. / European Journal of Medicinal Chemistry 187 (2020) 1119632chemotherapeutic agents for cancer treatment. In the context of
antimalarial therapy, several metal-containing molecules have
previously demonstrated to exert antiparasitic activity [8e12].
Ferroquine (FQ) (Fig. 1), a ferrocene-containing quinoline, has been
developed as an important antimalarial agent and is currently in
Phase II human clinical trials for uncomplicated P. falciparum ma-
laria [3,13e15]. Designing new drugs based on FQ led to the prep-
aration of numerous analogues, exemplified in Fig. 1 [13e16].
However, up to date, none of these analogues are able to compete
with FQ in terms of antimalarial activity.
As a part of a project aimed at the preparation of new potentially
bioactive ferrocene derivatives, we recently reported the synthesis
of bioactive 2-ferrocenoyl ethyl aryl amines by aza-Michael addi-
tions of anilines across 1-ferrocenylpropenone [17,18]. 2-
Ferrocenoyl ethyl aryl amines - Mannich bases - have proven to
be excellent starting materials for further synthesis of ferrocene
derivatives featuring a heterocyclic scaffold [19,20]. Bearing in
mind all the above, we planned to synthesize a small library of
ferrocenyl Mannich bases containing a quinoline core instead of a
benzene ring in order to evaluate their antiplasmodium activity and
use them for further synthetic transformations. Thus, herein we
present the synthesis, structural and electrochemical character-
ization, as well as the pharmacological evaluation of three different
sets of new ferrocene-quinoline conjugates: 1-ferrocenyl-3-(qui-
nolinylamino)propan-1-ones, 1-ferrocenyl-3-(quinolinylamino)
propan-1-ols, N-(3-ferrocenylprop-2-en-1-yl)-2,2,2-trifluoro-N-
(quinolinyl)acetamides and a class of novel ferrocene-containing
heterotricyclic products [21].
2. Results and discussion
2.1. Synthesis and structural characterization of novel ferrocene-
containing compounds
The first step in our approach concerned the development of a
suitable method for the synthesis of 1-ferrocenyl-3-(quinolinyla-
mino)propan-1-ones. A few years ago, we designed and optimized
reaction conditions for the synthesis of 3-arylamino-1-
ferrocenylpropan-1-ones in high yields, which have been shownFig. 1. Examples of some antimalarial quinolito be both biological active agents and excellent starting materials
for further chemical modifications [17e20]. Thus, this protocol was
adapted for the synthesis of our target compounds by using 4-
aminoquinoline as the arylamino moiety (see Scheme 1). Unfor-
tunately, after mixing 1 mmol of 1-ferrocenylpropenone 3 (syn-
thesized via a previously described method [17e20]), 1.5 mmol of
4-aminoquinoline 4a and 100 mg (0.42 mass equivalents) of
montmorillonite K-10 clay in an ultrasound bath for 1 h, the desired
compound could not be obtained (see Table 1, entry 1). Slight
modifications of these conditions weren’t satisfying either (see
Table 1, entries 2e4), as the maximum yield that could be obtained
via this method was 24% (see Table 1, entry 4), which was much
lower compared with the previously synthesized 3-arylamino-1-
ferrocenylpropan-1-ones via this protocol. These results promp-
ted us to change our approach and to use aza-Michael additions of
amines to enones, catalyzed by 0.1 M Na2CO3, as described by Xiao-
Ji Tang et al. [22] Applying these conditions to the reaction (see
Table 1, entry 5), we successfully synthesized 1-ferrocenyl-3-(qui-
nolin-4-ylamino)propan-1-one 5a in 19% yield. Again, we slightly
varied and modified these reaction conditions (see Table 1, entries
6e7) and established the optimal parameters by augmenting the
amount of Na2CO3 from 0.2 to 0.5 equivalents (see Table 1, entry 7).
With the optimal conditions in hand, the scope of the reaction was
investigated deploying four additional aminoquinolines 4b-e, with
a different substitution pattern. The products were obtained in
good to excellent yields (up to 91%) after purification by means of
column chromatography (SiO2), as shown in Table 2. Structural
characterization was made by spectroscopic methods (NMR, IR and
MS) and revealed a purity of >95% for all derivatives.
The obtained amino ketones 5a-e were then converted into the
corresponding 1,3-amino alcohols. For the reduction of ketones 5,
NaBH4 (five equivalents) in MeOH was employed, which lead to 1-
ferrocenyl-3-(quinolinylamino)propan-1-ols 6a-e in high yields (up
to 98%), with short reaction times (see Schemes 2 and 3). Note-
worthy, despite the efficient reduction process, all synthesized
compounds had to be purified by column chromatography (SiO2) to
obtain products with a purity >95%, confirmed by NMR and LC-MS
analysis. Because in general g-amino alcohols represent versatile
synthons in organic chemistry, the obtained ferrocene-containingnes bearing a ferrocene nucleus [13e16].
Scheme 1. Synthesis of 1-ferrocenyl-3-(quinolin-4-ylamino)propan-1-one 5a starting from 1-ferrocenylpropenone 3 and 4-aminoquinoline 4a.
Table 1
Attempts towards the synthesis of 1-ferrocenyl-3-(quinolin-4-ylamino)propan-1-one 5a.
Entry Catalyst Eq. 4a Time (h) Yield (%)a
1 0.42 m-eq. montmorillonite K-10, ultrasound bath 1.5 1 /
2 0.42 m-eq. montmorillonite K-10, ultrasound bath 1.5 3 /
3 0.42 m-eq. montmorillonite K-10, ultrasound bath 1.5 5 Traces
4 0.42 m-eq. montmorillonite K-10, ultrasound bath 2 6 24
5 0.2 equiv. 0.1 M Na2CO3, D 2 14 19
6 0.2 equiv. 0.1 M Na2CO3, D 2 20 22
7 0.5 equiv. 0.1 M Na2CO3, D 2 16 57
a Isolated yields after purification.
Table 2
Substrate scope for the synthesis of 1-ferrocenyl-3-(quinolinylamino)propan-1-ones 5a-e.
Entry Substrate Compound Yield (%)a
1 4a 5a 57
2 4b 5b 71
3 4c 5c 90
4 4d 5d 87
5 4e 5e 91
a Isolated yields after purification.
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themselves, represent excellent starting materials for further syn-
thesis of ferrocene-containing compounds with interesting bio-
logical properties (antibacterial, antimalarial, anti-inflammatory,
antitumor etc.) [23,24].
Therefore, the second part of our synthetic design comprised the
evaluation of 1-ferrocenyl-3-(quinolinylamino)propan-1-ols 6 as
substrates for the synthesis of functionalized ferrocene-containing
quinoline conjugates, which represent new classes of compounds
with great potential as biologically relevant structures (see
Schemes 2 and 3). As mentioned in the introduction, ferrocene-
quinoline conjugates are valuable new targets in medicinal chem-
istry, especially as antimalarial agents, because of the combined
properties of the ferrocene moiety and the aminoquinoline core (asestablished antiplasmodium pharmacophores). Within that
framework, we decided to transform 1-ferrocenyl-3-(quinolinyla-
mino)propan-1-ols 6a-e into unprecedented N-(3-ferrocenylprop-
2-en-1-yl)-2,2,2-trifluoro-N-(quinolinyl)acetamides 7a-e on the
one hand and heterotricyclic products 8a-e on the other hand, in
order to evaluate the antiplasmodium activity of these two new
compound classes as well.
A first route involved the transformation of 1-ferrocenyl-3-
(quinolinylamino)propan-1-ols 6a-e into N-(3-ferrocenylprop-2-
en-1-yl)-2,2,2-trifluoro-N-(quinolinyl)acetamides 7a-e upon treat-
ment with triethylamine (1.5 equivalents) and trifluoroacetic an-
hydride (1.5 equivalents) in dry tetrahydrofuran at 0 C (see Scheme
2, route b). Crude mixtures were purified by means of column
chromatography (SiO2) to afford amides 7a-e in good yields (up to
Scheme 2. Synthetic route to ferrocene-containing compounds 6, 7 and 8: (a) 5 equiv. NaBH4, MeOH, 2 h, r.t., (b) 1.5 equiv. Et3N, 1.5 equiv. (CF3CO)2O, dry THF, N2 atmosphere, 16 h,
0 C, (c) glacial acetic acid, ultrasound irradiation, 2 h, r.t.
Scheme 3. Overview of synthesized new ferrocene-containing heterocycles 6, 7 and 8.
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Fig. 3. Molecular structures of ferrocene-quinoline conjugate 7d, showing thermal
displacement ellipsoids at the 50% probability level.
Fig. 4. Molecular structure of ferrocene-quinoline conjugate 8e, showing thermal
displacement ellipsoids at the 50% probability level.
A. Minic et al. / European Journal of Medicinal Chemistry 187 (2020) 111963 587%, see Scheme 3) and high purity (>95%, confirmed by NMR and
LC-MS analysis). Based on 1H NMR analysis, we concluded that all
compounds 7a-e possessed a double bond with E-configuration,
since their olefinic protons showed a coupling constant of
15.5e15.6 Hz, which is a typical value for E-alkenes. Moreover, X-
ray analysis was performed on a sample of compound 7d (see
Fig. 3), which revealed the presence of two invertomers with a
different orientation of the three substituents around the aliphatic
nitrogen atom due to hindered rotation.
In a second route, ferrocene-containing tricyclic compounds 8
were premised (see Scheme 2, route c). For this synthetic approach,
a method previously reported by us was applied [20], which is
efficient and requires mild reaction conditions. Results obtained by
this transformation clearly show that 1-ferrocenyl-3-(quinolinyla-
mino)propan-1-ols 6a-e can smoothly undergo an intramolecular
Friedel-Crafts-type reaction promoted by acetic acid, giving rise to
the corresponding new heterotricycles 8a-e in high to excellent
yields (up to 98%, see Scheme 3).
For structures 6b and 6d, the formation of two cyclization
products 8 is possible, because these compounds have two ortho
positions relative to the amino functionality, which can give rise to
two different positions for ring closure (see ESI Scheme S1 and
Scheme S2). Interestingly, our study revealed that even though
formation of two products was anticipated, in both cases only one
product was obtained. The structures of 8b and 8d have been
determined based on chemical shifts and coupling constants from
the protons of the quinoline nucleus of the heterotricyclic part in 1H
NMR spectra, which in both cases could exclude the formation of
the other predicted product (see Fig. 2 and experimental part). In
addition, these results have been also confirmed using 2D NMR
spectroscopy (HMBC, HSQC and NOESY, see ESI). Full confirmation
of this set of heterotricyclic compounds 8was obtained bymeans of
NMR, IR and LC-MS analysis for all derivatives and X-ray analysis for
compound 8e (see Fig. 4).2.2. Electrochemistry
It is well known that the Fe2þ/Fe3þ redox chemistry contributesFig. 2. Aromatic part of 1H NMR speto the bioactivity of ferrocene derivatives [17,19,26e29]. In view of
that, we decided to evaluate the electrochemical properties of all
newly synthesized compounds 5a-e, 6a-e, 7a-e and 8a-e. This was
done by means of cyclic voltammetry (CV) in dichloromethane
containing 0.1 mol/L tetrabutylammonium perchlorate as a sup-
porting electrolyte. The working electrode was a polished (2mm
diameter; Metrohm). The counter electrode was a platinum wire,
whereas an Ag/AgCl electrode was used as the reference. The peak
potentials (Ep) of the anodic and cathodic potentials (Epa and Epc,
respectively, at 0.1 V s1), their half-wave potentials (E1/2 ¼ctra for compounds 8b and 8d.
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peak potentials (DE ¼ Epa ‒ Epc) of the ferrocenyl-derivatives 5a-e,
6a-e, 7a-e and 8a-e are measured and evaluated as important
electrochemical data [30]. All measurements were carried out using
ferrocene as internal standard. In addition, CV measurements
provide an additional proof of purity of our biologically investi-
gated samples.Fig. 5. Cyclic voltammograms at the platinum disk (d ¼ 2 mm) by a 0.1 V s1 scan rate
in 0.1 M dichloromethane solution of Bu4NClO4: (a) electrolyte, (b) 1-ferrocenyl-3-
(quinolin-8-ylamino)propan-1-one (5e), (c) ferrocene.
Table 4
The electrochemical data for compounds 6a-e.
Compound Epa2 (V)a Epa3 (V)a Epc2 (V)a E1/2 (V)b DE (V)c
6a 0.571 1.105 0.427 0.499 0.144
6b 0.623 1.074 0.381 0.502 0.242
6c 0.613 0.943 0.385 0.499 0.228
6d 0.595 0.967 0.406 0.501 0.1892.2.1. Electrochemical properties of 1-ferrocenyl-3-
(quinolinylamino)propan-1-ones 5a-e
The cyclic voltammogram of compound 5e is shown (see Fig. 5
and ESI Fig. S10 and Fig. S11), as representative example, whereas
the data for the other compounds are listed in Table 3. The 1-
ferrocenyl-3-(quinolinylamino)propan-1-ones 5a-e exhibit a
reversible one-electron redox couple, as can be seen in Fig. 5.
Oxidation wave (O1) appeared at 0.981 V, whereas the reduction
wave (R1) showed up at 0.598 V, and we attributed them to the
oxidation of the ferrocene unit during the forward-potential sweep,
and the reduction of the obtained ferricenium ion at the back-
potential sweep. It appears that the oxidation potentials of 5a-e
are considerably more positive than the ones of the unsubstituted
ferrocenes (Fcþ/Fc ¼ 0.640 V), which can be expected for ferrocene
derivatives possessing an electron-withdrawing group conjugated
to the cyclopentadienyl ring(s) [17,19,25]. This result shows signif-
icant electronic contact between the ferrocenyl units and the rest of
the molecule. In addition, calculated DE (>0.250 V) for compounds
5a-e are higher than the theoretical value (DE ¼ 0.150 V) for
reversible couples, which indicates the quasi-reversible nature of
the system [30] also observed in similar monoferrocenyl de-
rivatives [17,19,25].6e 0.650 0.888 0.345 0.498 0.305
a Epa and Epc anodic and cathodic peak potentials, respectively, at 0.1 V s1
b E1/2 ¼ (Epa2 þ Epc2)/2.
c DE ¼ Epa2 ‒ Epc2.2.2.2. Electrochemical properties of 1-ferrocenyl-3-
(quinolinylamino)propan-1-ols 6a-e
Data obtained from electrochemical evaluation of 1-ferrocenyl-
3-(quinolinylamino)propan-1-ols 6a-e are summarized in Table 4.
All ferrocene-containing amino alcohols exhibit two well-defined
oxidation waves on the forward-potential sweep (O2, at around
0.650 V and O3, at around 0.888 V, respectively) and one reduction
wave during the back-potential sweep (R2, at around 0.345 V). The
representative cyclic voltammograms recorded for compound 6e
are illustrated in Fig. 6 (see also ESI Fig. S12). As it can be seen, the
first oxidation peak (O2) occurred at 0.650 V while the corre-
sponding anodic (R2) signal appeared at 0.345 V (see Fig. 6). We
believe that these peaks correspond to the same redox couple,
probably ferrocene/ferrocenium. It is noteworthy that if we
compare forward-potential sweep oxidation waves of 6a-e (O2 at
around 0.650 V) with 5a-e (O1 at around 0.981 V) and with the
ones of the unsubstituted ferrocenes (Fcþ/Fc ¼ 0.640 V), we can
show the influence of the carbonyl group and hydroxyl group
(bonded onto the a-ferrocenyl carbon atom) on the values of
oxidation potentials [17,19,25]. On the other hand, the second
oxidation wave (O3) is occurring due to an irreversibleTable 3
The electrochemical data for compounds 5a-e.
Compound Epa1 (V)a Epc1 (V)a E1/2 (V)b DE (V)c
5a 0.909 0.647 0.778 0.262
5b 0.919 0.653 0.786 0.266
5c 0.909 0.644 0.777 0.265
5d 0.928 0.656 0.792 0.272
5e 0.981 0.598 0.790 0.383
a Epa and Epc anodic and cathodic peak potentials, respectively, at 0.1 V s1
b E1/2 ¼ (Epa1 þ Epc1)/2.
c DE ¼ Epa1 ‒ Epc1.
Fig. 6. Cyclic voltammograms at the platinum disk (d ¼ 2 mm) by a 0.1 V s1 scan rate
in 0.1 M dichloromethane solution of Bu4NClO4: (a) electrolyte, (b) 1-ferrocenyl-3-
(quinolin-8-ylamino)propan-1-ol (6e), (c) ferrocene.electrochemical event. The origin of this second oxidation wave
(O3) is established by linking structure and electrochemical prop-
erties of compounds 5a-e with 6a-e, and it can be assigned to the
oxidation of the hydroxyl group. The voltammograms of 6e at both
higher and lower scan rates also contained peak O3 (see ESI
Fig. S13), suggesting the stability of the oxidized species in solution
Fig. 7. Cyclic voltammograms at the platinum disk (d ¼ 2 mm) by a 0.1 V s1 scan rate
in 0.1 M dichloromethane solution of Bu4NClO4: (a) electrolyte, (b) N-(3-
ferrocenylprop-2-en-1-yl)-2,2,2-trifluoro-N-(quinoline-3-yl)acetamide (7b), (c)
ferrocene.
Fig. 8. Cyclic voltammograms at the platinum disk (d ¼ 2 mm) by a 0.1 V s1 scan rate
in 0.1 M dichloromethane solution of Bu4NClO4: (a) electrolyte, (b) 1-Ferrocenyl-
1,2,3,4-tetrahydrobenzo[f] [1,7]naphthyridine (8b), (c) ferrocene.
Table 6
The electrochemical data for compounds 8a-e.
Compound Epa5 (V)a Epa6 (V)a Epc4 (V)a Epc5 (V)a E1/2 (V)b DE (V)c
8a 0.641 e e 0.476 0.559 0.174
8b 0.592 e e 0.470 0.531 0.122
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2.2.3. Electrochemical properties of N-(3-ferrocenylprop-2-en-1-
yl)-2,2,2-trifluoro-N-(quinolinyl)acetamides 7a-e
The redox behavior of the products 7a-e was determined using
cyclic voltammetry (CV) under the same conditions mentioned
above, and the results of this study are listed in Table 5. Based on
these data, we can conclude that all novel ferrocene-containing
derivatives 7a-e exhibit one well-defined oxidation wave on the
forward-potential sweep (O4 at 0.671e0.933 V) and one reduction
wave during the back-potential sweep (R3 at 0.348e0.491 V),
attributed to the ferrocene moiety. As a representative example, we
present the cyclic voltammogram of compound 7b (see Fig. 7 and
ESI Fig. S14). Due to the reversibility of this electron transfer, even at
low scan speed, the produced radical anion is stablewithin the time
scale of cyclic voltammetry (see ESI Fig. S15) [30]. Moreover, the
average of anodic and cathodic current was not unity and the dif-
ference between the oxidation and reduction maxima (DE ¼ Epa4 ‒
Epc3) was around 0.355. Compared with the theoretical value
DE ¼ 0.150 V, we can confirm the quasi-reversible nature of the
system [30].
2.2.4. Electrochemical properties of ferrocene-containing tricyclic
products 8a-e [21]
The voltammogram of compound 8b is presented in Fig. 8, as
representative example, whereas the data of the other compounds
8a-e are listed in Table 6. As it can be seen from the summarized
data, derivatives 8a-d exhibit one well-defined oxidation wave on
the forward potential sweep (O5, at 0.592e0.653 V) and one
reductionwave on the back-potential sweep (R5, at 0.403e0.476 V).
Since the difference between the values of these two potentials is
close to the theoretical one, O5 and R5 apparently belong to a
reversible redox couple, appearing due to the presence of the
ferrocene nucleus [17,19,25,29]. Noteworthy, a considerable differ-
ence is observed for compound 8e (see Table 6). Therefore, the
cyclic voltammogram recorded for 8e is shown in Fig. 9. Apparently,
8e exhibit two well-defined oxidation waves on the forward po-
tential sweep (O5, at 0.626 V and O6, at 0.940 V, respectively) and
two reduction waves on the back-potential sweep (R4, at 0.659 V
and R5, at 0.403 V, respectively). Considering the reversibility of
ferrocene oxidation, the first redox couple (O5 and R5) certainly can
be assigned to the metallocene moiety. On the other hand, the
origin of the second redox wave is difficult to determine precisely,
but it could potentially be correlated with the redox process of the
tricyclic scaffold. The electrochemical properties of these series of
ferrocenyl derivatives 8a-e are highly interesting and warrant
additional investigation [30], albeit both the extent and the type of
further investigations are beyond the scope of this work.
2.3. Antiplasmodium activities
With this small library of ferrocene-quinolines and ferrocene-Table 5
The electrochemical data for compounds 7a-e.
Compound Epa4 (V)a Epc3 (V)a E1/2 (V)b DE (V)c
7a 0.671 0.491 0.581 0.180
7b 0.781 0.430 0.606 0.351
7c 0.933 0.348 0.641 0.585
7d 0.732 0.449 0.591 0.283
7e 0.812 0.439 0.626 0.373
a Epa and Epc anodic and cathodic peak potentials, respectively, at 0.1 V s1
b E1/2 ¼ (Epa4 þ Epc3)/2.
c DE ¼ Epa4 ‒ Epc3.
8c 0.641 e e 0.458 0.550 0.183
8d 0.653 e e 0.406 0.530 0.247.
8e 0.626 0.940 0.659 0.403 0.515 0.223
a Epa and Epc anodic and cathodic peak potentials, respectively, at 0.1 V s1
b E1/2 ¼ (Epa5 þ Epc5)/2.
c DE ¼ Epa5 ‒ Epc5.containing heterotricyclic derivatives in hand, pharmacological
screening was performed. All 20 ferrocene derivatives were sub-
jected to antiplasmodium testing. For the antiplasmodium assay, all
samples were tested in triplicate against a chloroquine-sensitive
(CQS) strain of Plasmodium falciparum (NF54). Subsequently,
Fig. 9. Cyclic voltammograms at the platinum disk (d ¼ 2 mm) by a 0.1 V s1 scan rate
in 0.1 M dichloromethane solution of Bu4NClO4: (a) electrolyte, (b) 4-Ferrocenyl-
1,2,3,4-tetrahydro-1,10-phenanthroline (8e), (c) ferrocene.
Table 8
IC50 values of ferrocene-quinolines 5a, 6a and 7a tested for in vitro antimalarial
activity (against a CQR P. falciparum strain) and cytotoxicity. Data are expressed as
mean ± SD values of three independent experiments.
Compound NF54: IC50 (mM) K1: IC50 (mM) CHO: IC50 (mM) SIa RIb
5a 0.85 ± 0.25 3.91 ± 0.07 251.68 ± 12.10 296.2 4.6
6a 0.39 ± 0.01 0.77 ± 0.07 23.14 ± 1.71 59.3 2.0
7a 0.93 ± 0.15 0.82 ± 0.05 19.90 ± 1.99 21.5 0.9
CQ 0.011 ± 0.001 0.167 ± 0.028 e e 14.7
FQ 0.029 ± 0.001 0.039 ± 0.003 e e 1.3
Emetine (mM) e e 0.04 ± 0.01 e e
CQ ¼ chloroquine.
FQ ¼ ferroquine.
a SI (Selectivity Index) ¼ IC50 CHO/IC50 NF54.
b RI (Resistance Index) ¼ IC50 K1/IC50 NF54.
A. Minic et al. / European Journal of Medicinal Chemistry 187 (2020) 1119638samples that showed promising antiplasmodium activity (i.e.
compounds 5a, 6a and 7a) were tested in triplicate against a
chloroquine-resistant (CQR) strain of P. falciparum (K1) and
screened for in vitro cytotoxicity against a mammalian cell-line,
Chinese Hamster Ovarian (CHO), using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-
assay, also in triplicate. Chloroquine was used as a reference com-
pound in the antiplasmodium assays, whereas the antiprotozoal
agent emetine was used in the cytotoxicity tests as positive control.
Continuous in vitro cultures of asexual erythrocyte stages of
P. falciparum were maintained using a modified method of Trager
and Jensen [31]. Quantitative assessment of antiplasmodium ac-
tivity in vitro was determined via the parasite lactate dehydroge-
nase assay using a modified method described by Makler [32]. The
MTT-assay was used as colorimetric assay to measure cell growth
and survival and compares well with other available assays [33,34].
The results of the biological evaluation are summarized in Tables 7
and 8.
It can be seen that various analogues show weak to good ac-
tivities (IC50 < 10 mM), with three of the tested compounds showing
submicromolar (IC50 < 1 mM) potencies against a chloroquine-Table 7
IC50 values for ferrocene-quinolines (5, 6, and 7) and ferrocene-containing hetero-
tricyclic derivatives (8) tested for in vitro antimalarial activity against a CQS
P. falciparum strain. Data are expressed as mean ± SD values of three independent
experiments.
Compound NF54: IC50 (mM) Compound NF54: IC50 (mM)
5a 0.85 ± 0.25 7a 0.93 ± 0.15
5b 5.75 ± 0.21 7b 12.18 ± 0.50
5c 3.13 ± 0.33 7c 19.26 ± 1.59
5d 5.36 ± 1.16 7d 17.47 ± 4.58
5e 27.79 ± 0.91 7e 12.21 ± 0.42
6a 0.39 ± 0.01 8a 1.69 ± 0.35
6b 5.63 ± 0.68 8b 82.76 ± 17.53
6c 3.99 ± 1.26 8c 22.35 ± 2.02
6d 9.65 ± 0.75 8d 39.49 ± 2.26
6e 21.08 ± 3.29 8e 30.44 ± 4.78
CQ 0.011 ± 0.001
FQ 0.029 ± 0.001
CQ ¼ chloroquine.
FQ ¼ ferroquine.sensitive NF54 strain of P. falciparum (with IC50 values between
390 and 930 nM). However, ferrocene-containing heterotricyclic
derivatives gave no significant activity (except derivative 8a,
IC50 ¼ 1.69 mM). Subsequently, the activity of the three most potent
compounds (5a, 6a and 7a) was determined against a chloroquine-
resistant strain of P. falciparum (K1), which resulted in promising
activities with IC50 values of 3.91, 0.77 and 0.82 mM, respectively
(see Table 8). Moreover, these three derivatives also displayed a
good cytotoxicity profile (lower activities against CHO, resulting in
high selectivity indices). Regarding the structure-activity relation-
ships, this assay shows that the best activities are obtained when
ferrocene is linked to the quinoline ring at position 4, since com-
pounds 5a, 6a, 7a and 8a are the four most potent compounds. Next
to that, compounds 6a and 7a possess a lower (so a better) Resis-
tance Index than compound 5a, bearing a keto functional group. On
the other hand, derivative 5a has the best Selectivity Index. Due to
the diversity of this library (focusing on various substitution pat-
terns across the quinoline core and also the linker between ferro-
cene and quinoline ring), these results cannot be generalized, but
they can be seen as a valuable starting point for further research on
4-functionalized ferrocene-quinolines.3. Conclusion
Preparation of three series of novel ferrocene-quinoline hybrids
and ferrocene-containing heterotricycles was achieved using a
simple and efficient synthetic protocol. Structures of novel com-
pounds were confirmed by standard spectral techniques (NMR, IR
and MS), and the proposed structures of two representative prod-
ucts 7d and 8ewere also secured by single-crystal X-ray diffraction
analysis. The cyclic voltammetry studies confirmed the previously
reported correlation between electrochemical behavior and the
biological activity of ferrocenes and revealed that derivatives 5a-e
and 7a-e showed a single-electron reversible oxidation behavior
attributed to the ferrocene nucleus, whereas products 6a-e
exhibited two well-defined oxidation waves and one reduction
wave (O2 and R2 assigned to the metallocene unit and O3 assigned
to the hydroxy group). Electrochemical evaluation of compounds
8a-e showed that products 8a-d exhibited only one well-defined
redox couple (attributed to the ferrocene nucleus), whereas prod-
uct 8e exhibited two well-defined redox couples.
Furthermore, the in vitro antiplasmodium activity and cytotox-
icity of the novel ferrocene-containing compounds was evaluated.
Compounds 5a, 6a and 7a displayed low micromolar activity
against a chloroquine-sensitive strain of P. falciparum, and com-
pounds 6a and 7a also exhibited a submicromolar activity against a
chloroquine-resistant strain of P. falciparumwith IC50-values of 0.77
and 0.82 mM, respectively, accompanied by low cytotoxicity. In view
of their low micromolar antiplasmodium activities, high selectivity
A. Minic et al. / European Journal of Medicinal Chemistry 187 (2020) 111963 9indices and low resistance indices, both ferrocene-quinoline con-
jugates 6a and 7a can be considered as valuable new hit molecules
for elaboration follow-up studies in malaria research.
4. Experimental section
4.1. Chemistry
4.1.1. General
All chemicals were commercially available and used as received,
except the solvents, which were purified by distillation.
Chromatographic separations were carried out using silica gel
60 (particle size distribution 40e63 mm) purchased from Merck
(Darmstadt, Germany), whereas silica gel plates (Merck Silicagel 60
F254, precoated, layer thickness 0.25 mm) was used for TLC. Proton
(1H) and Carbon (13C) NMR spectra were recorded on a Bruker
Avance III 400 spectrometer (400 MHz for 1H, 101 MHz for 13C).
Solutions were prepared in deuterochloroform (CDCl3) and chem-
ical shifts are expressed in ppm (d) using tetramethylsilane as the
internal standard. 2D experiments (COSY, NOESY, HSQC and HMBC)
were run on the Bruker Avance III 400 spectrometer with the usual
pulse sequences. HPLC-MS analyses were performed on an Agilent
1200 series HPLC system equipped with a Supelco Ascentis Express
C18 column (3 cm  4.6 mm, 2.7 mm fused-core particles, 90 Å),
Phenomex Guard column (SecurityGuard Standard) and a UV-DAD
detector. The HPLC is coupled to an Agilent 1100 Series MS with
electrospray ionization (70 eV) with a single quadrupole detector.
The IR measurements were carried out in neat formwith an ATR
(Attenuated Total Reflectance) accessory with a Shimadzu
IRAFFINITY-1S WL FTIR spectrophotometer.
The GC/MS analyses were performed on a Hewlett-Packard
6890/5973N gas chromatograph/mass spectrometer equipped
with a Phenomex Zebron ZB-5MSplus (30m 0.25mm 0.25 mm)
column and quadrupole mass analyzer (Electron Ionization, 70 eV).
Cyclic voltammetry experiments were performed at room tem-
perature in a standard three-electrode cell using an Autolab
potentiostat (PGSTAT 302 N). The working electrode was a plat-
inum disk (2 mm diameter; Metrohm). The counter electrode was a
platinum wire, whereas an Ag/AgCl electrode was used as the
reference. Prior to experiments, the working electrode was pol-
ished using Metrohm polishing kit 6.2802.000 (extremely fine
aluminum oxide on a cloth), followed by washing with distilled
water.
Melting points were measured on a Mel-Temp cap. Melting
points apparatus, model 1001, and the given values are uncorrec-
ted. Ultrasonic cleaner Elmasonic S 10, 30 W was used for the ul-
trasonically supported synthesis.
4.1.2. General procedure for the synthesis of 1-ferrocenyl-3-
(quinolinylamino)propan-1-ones (5a-e)
A solution of the corresponding aminoquinoline (2 mmol) and
1-ferrocenylpropenone 3 [17e20] (1 mmol) in 0.1 M Na2CO3
(0.5 mmol, 5 ml) was stirred at reflux conditions overnight (around
15 h). The reaction mixturewas quenched by addition of cold water
(20 ml) and the products were extracted with CH2Cl2 (two 20 ml
portions). The organic layer was washed with brine and dried over
anh. Na2SO4. After evaporation of the solvent, the crude mixture
was purified by column chromatography (SiO2), affording pure
products 5a-e.
4.1.2.1. 1-Ferrocenyl-3-(quinolin-4-ylamino)propan-1-one (5a).
Dark orange solid; mp 162 C. Rf ¼ 0.38 (EtOAc/MeOH, 9:1 (v/v)).
Yield 57%. 1H NMR (400 MHz, CDCl3): d ¼ 8.60 (d, J ¼ 5.3 Hz, 1H,
CHAr), 7.97 (d, J¼ 8.3 Hz,1H, CHAr), 7.77 (d, J¼ 8.4 Hz,1H, CHAr), 7.62
(ddd, J ¼ 8.4, 7.0, 1.3 Hz, 1H, CHAr), 7.44 (ddd, J ¼ 8.3, 7.0, 1.1 Hz, 1H,CHAr), 6.51 (d, J ¼ 5.3 Hz, 1H, CHAr), 5.84 (t, J ¼ 5.8 Hz, 1H,
CH2CH2NH), 4.80 (pseudo t, J¼ 1.9 Hz, 2H, 2 CHCp), 4.54 (pseudo t,
J ¼ 1.9 Hz, 2H, 2  CHCp), 4.09 (s, 5H, 5  CHCp), 3.80 (td, J ¼ 5.9,
5.8 Hz, 2H, CH2CH2NH), 3.15 (t, J¼ 5.9 Hz, 2H, CH2CH2NH). 13C NMR
(101 MHz, CDCl3): d ¼ 203.4 (C]O), 150.5 (CAr), 149.6 (CAr), 148.1
(CAr), 129.5 (CAr), 129.3 (CAr), 124.9 (CAr), 119.6 (CAr), 118.9 (CAr), 98.4
(CAr), 78.4 (CCp), 72.8 (2  CCp), 69.9 (5  CCp), 69.3 (2  CCp), 38.1
(CH2CH2NH), 37.5 (CH2CH2NH). IR (ATR, cm1): n ¼ 3210 (NeH)
cm1; n ¼ 1651 (C]O) cm1. MS (70eV): m/z (%) 385.0 ([M þ H]þ).
HRMS (ESI): m/z for C22H20FeN2O [MþH]þ calcd 385.0998, found
385.0991.
4.1.2.2. 1-Ferrocenyl-3-(quinolin-3-ylamino)propan-1-one (5b).
Dark orange solid; mp 166 C. Rf ¼ 0.72 (EtOAc/MeOH, 9:1 (v/v)).
Yield 71%. 1H NMR (400 MHz, CDCl3): d ¼ 8.46 (d, J ¼ 2.8 Hz, 1H,
CHAr), 7.96e7.91 (m, 1H, CHAr), 7.65e7.62 (m, 1H, CHAr), 7.46e7.38
(m, 2H, 2  CHAr), 7.10 (d, J ¼ 2.8 Hz, 1H, CHAr), 4.79 (pseudo t,
J ¼ 1.9 Hz, 2H, 2  CHCp), 4.60 (t, J ¼ 6.2 Hz, 1H, CH2CH2NH), 4.53
(pseudo t, J ¼ 1.9 Hz, 2H, 2  CHCp), 4.15 (s, 5H, 5  CHCp), 3.67 (td,
J ¼ 6.2, 6.2 Hz, 2H, CH2CH2NH), 3.11 (t, J ¼ 6.2 Hz, 2H, CH2CH2NH).
13C NMR (101 MHz, CDCl3): d 203.3 (C]O), 143.6 (CAr), 142.2 (CAr),
141.2 (CAr), 129.4 (CAr), 129.1 (CAr), 127.0 (CAr), 125.9 (CAr), 125.0
(CAr), 110.2 (CAr), 78.6 (CCp), 72.7 (2  CCp), 69.9 (5  CCp), 69.3
(2  CCp), 38.6 (CH2CH2NH), 37.9 (CH2CH2NH). IR (ATR, cm1):
n ¼ 3363 (NeH) cm1; n ¼ 1645 (C]O) cm1. MS (70eV): m/z (%)
385.0 ([M þ H]þ). HRMS (ESI): m/z for C22H20FeN2O [MþH]þ calcd
385.0998, found 385.1011.
4.1.2.3. 1-Ferrocenyl-3-(quinolin-5-ylamino)propan-1-one (5c).
Dark orange solid; mp 125 C. Rf ¼ 0.82 (EtOAc/MeOH, 9:1 (v/v)).
Yield 90%. 1H NMR (400 MHz, CDCl3): d ¼ 8.85 (dd, J ¼ 4.1, 1.3 Hz,
1H, CHAr), 8.21 (d, J ¼ 8.6 Hz, 1H, CHAr), 7.59 (dd, J ¼ 8.4, 7.7 Hz, 1H,
CHAr), 7.49 (d, J ¼ 8.4 Hz, 1H, CHAr), 7.32 (dd, J ¼ 8.6, 4.1 Hz, 1H,
CHAr), 6.71 (d, J ¼ 7.7 Hz, 1H, CHAr), 5.24 (br s, 1H, CH2CH2NH), 4.79
(pseudo t, J ¼ 1.9 Hz, 2H, 2  CHCp), 4.52 (pseudo t, J ¼ 1.9 Hz, 2H,
2 CHCp), 4.09 (s, 5H, 5 CHCp), 3.73 (t, J¼ 5.8 Hz, 2H, CH2CH2NH),
3.15 (t, J ¼ 5.8 Hz, 2H, CH2CH2NH). 13C NMR (100 MHz, CDCl3):
d ¼ 204.0 (C]O), 150.1 (CAr), 149.3 (CAr), 143.4 (CAr), 130.3 (CAr),
129.0 (CAr), 119.6 (CAr), 118.8 (CAr), 118.6 (CAr), 104.5 (CAr), 78.6 (CCp),
72.7 (2  CCp), 69.9 (5  CCp), 69.3 (2  CCp), 39.2 (CH2CH2NH), 37.7
(CH2CH2NH). IR (ATR, cm1): n ¼ 3293 (NeH) cm1; n ¼ 1659 (C]
O) cm1. MS (70eV): m/z (%) 385.0 ([M þ H]þ).
4.1.2.4. 1-Ferrocenyl-3-(quinolin-6-ylamino)propan-1-one (5d).
Dark orange solid; mp 130 C. Rf ¼ 0.85 (EtOAc/MeOH, 9:1 (v/v)).
Yield 87%. 1H NMR (400MHz, CDCl3): d¼ 8.61 (dd, J¼ 4.1,1.2 Hz,1H,
CHAr), 7.93 (d, J¼ 8.3 Hz,1H, CHAr), 7.87 (d, J¼ 9.0 Hz,1H, CHAr), 7.26
(dd, J¼ 8.3, 4.1 Hz, 1H, CHAr), 7.11 (dd, J¼ 9.0, 2.4 Hz, 1H, CHAr), 6.78
(d, J ¼ 2.4 Hz, 1H, CHAr), 4.78 (pseudo t, J ¼ 1.7 Hz, 2H, 2  CHCp),
4.57 (t, J ¼ 5.6 Hz, 1H, CH2CH2NH), 4.52 (pseudo t, J ¼ 1.7 Hz, 2H,
2  CHCp), 4.12 (s, 5H, 5  CHCp), 3.68 (td, J ¼ 5.7, 5.6 Hz, 2H,
CH2CH2NH), 3.10 (t, J ¼ 5.7 Hz, 2H, CH2CH2NH). 13C NMR (100 MHz,
CDCl3): d ¼ 203.4 (C]O), 146.2 (CAr), 145.7 (CAr), 143.3 (CAr), 133.8
(CAr), 130.5 (CAr), 130.1 (CAr), 121.6 (CAr), 121.4 (CAr), 103.0 (CAr), 78.7
(CCp), 72.6 (2  CCp), 69.9 (5  CCp), 69.3 (2  CCp), 38.8
(CH2CH2NH), 38.0 (CH2CH2NH). IR (ATR, cm1): n ¼ 3329 (NeH)
cm1; n ¼ 1658 (C]O) cm1. MS (70eV): m/z (%) 385.0 ([M þ H]þ).
4.1.2.5. 1-Ferrocenyl-3-(quinolin-8-ylamino)propan-1-one (5e).
Dark orange solid; mp 127 C. Rf ¼ 0.48 (Toluene/EtOAc, 9:1 (v/v)).
Yield 91%. 1H NMR (400 MHz, CDCl3): d ¼ 8.71 (dd, J ¼ 4.2, 1.8 Hz,
1H, CHAr), 8.04 (dd, J¼ 8.3, 1.8 Hz,1H, CHAr), 7.42 (dd, J¼ 8.0, 7.8 Hz,
1H, CHAr), 7.35 (dd, J¼ 8.3, 4.2 Hz,1H, CHAr), 7.06 (dd, J¼ 8.0, 0.9 Hz,
1H, CHAr), 6.78 (dd, J ¼ 7.8, 0.9 Hz, 1H, CHAr), 6.42 (t, J ¼ 6.3 Hz, 1H,
CH2CH2NH), 4.80 (pseudo t, J¼ 1.9 Hz, 2H, 2 CHCp), 4.50 (pseudo t,
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6.3 Hz, 2H, CH2CH2NH), 3.17 (t, J¼ 6.6 Hz, 2H, CH2CH2NH). 13C NMR
(100 MHz, CDCl3): d ¼ 202.8 (C]O), 147.0 (CAr), 144.4 (CAr), 138.4
(CAr), 136.0 (CAr), 128.7 (CAr), 127.7 (CAr), 121.5 (CAr), 114.0 (CAr),
104.5 (CAr), 79.0 (CCp), 72.4 (2  CCp), 69.8 (5  CCp), 69.3 (2  CCp),
38.7 (CH2CH2NH), 38.1 (CH2CH2NH). IR (ATR, cm1): n ¼ 3400
(NeH) cm1; n ¼ 1664 (C]O) cm1. MS (70eV):m/z (%) 385.0 ([Mþ
H]þ).
4.1.3. General procedure for the synthesis of 1-ferrocenyl-3-
(quinolinylamino)propan-1-ols (6a-e)
To a stirred solution of the corresponding 1-ferrocenyl-3-(qui-
nolinylamino)propan-1-one 5a-e (1 mmol) in MeOH (20 ml) at
room temperature, an excess of NaBH4 (5 mmol) was added in
several portions (up to 190 mg) and the reaction progress was
monitored by TLC. After completion of the reduction (ca. 2 h),
methanol was distilled off and the residue was diluted with water
(20 ml). The mixture was extracted with CH2Cl2 (two 20 ml por-
tions) and the collected organic layers were washed with water and
brine and dried with anh. Na2SO4. After filtering off the drying
agent and evaporation of the solvent, the crude mixture was pu-
rified by column chromatography (SiO2), affording pure products
6a-e.
4.1.3.1. 1-Ferrocenyl-3-(quinolin-4-ylamino)propan-1-ol (6a).
Yellow solid; mp 172 C. Rf ¼ 0.47 (EtOAc/MeOH, 9:1 (v/v)). Yield
91%. 1H NMR (400 MHz, CDCl3) d ¼ 8.53 (d, J ¼ 5.3 Hz, 1H, CHAr),
7.98 (dd, J¼ 8.4, 1.0 Hz, 1H, CHAr), 7.73 (dd, J ¼ 8.4, 1.0 Hz, 1H, CHAr),
7.62 (ddd, J ¼ 8.4, 7.0, 1.0 Hz, 1H, CHAr), 7.42 (ddd, J ¼ 8.4, 7.0, 1.0 Hz,
1H, CHAr), 6.37 (d, J ¼ 5.3 Hz, 1H, CHAr), 6.11 (br s, 1H,
CHCH2CH2NH), 4.66 (dd, J ¼ 8.3, 3.4 Hz, 1H, CHOH), 4.29e4.27 (m,
1H, CHCp), 4.24e4.20 (m, 8H, 8  CHCp), 3.53e3.39 (m, 2H,
CHCH2CH2NH), 2.26e2.15 (m, 3H, CHOH and CHCH2CH2NH). 13C
NMR (101 MHz, CDCl3) d ¼ 150.8 (CAr), 150.1 (CAr), 148.0 (CAr), 129.5
(CAr), 129.1 (CAr), 124.6 (CAr), 119.7 (CAr), 118.8 (CAr), 98.3 (CAr), 93.3
(CCp), 69.9 (CHOH), 68.4 (5  CCp), 68.33 (CCp), 68.30 (CCp), 67.0
(CCp), 65.2 (CCp), 41.3 (CHCH2CH2NH), 36.0 (CHCH2CH2NH). IR (ATR,
cm1): n ¼ 3280 (NeH) cm1; n ¼ 3080 (OeH) cm1. MS (70eV):m/
z (%) 387.0 ([Mþ H]þ). HRMS (ESI): m/z for C22H22FeN2O [MþH]þ
calcd 387.1155, found 387.1163.
4.1.3.2. 1-Ferrocenyl-3-(quinolin-3-ylamino)propan-1-ol (6b).
Yellow solid; mp 146 C. Rf ¼ 0.82 (EtOAc/MeOH, 9:1 (v/v)). Yield
86%. 1H NMR (400 MHz, CDCl3): d ¼ 8.41 (d, J ¼ 2.8 Hz, 1H, CHAr),
7.95e7.91 (m, 1H, CHAr), 7.62e7.58 (m, 1H, CHAr), 7.44e7.36 (m, 2H,
2  CHAr), 6.99 (d, J ¼ 2.8 Hz, 1H, CHAr), 4.58 (dd, J ¼ 8.2, 4.1 Hz, 1H,
CHOH), 4.48 (t, J ¼ 4.9 Hz, 1H, CHCH2CH2NH), 4.28e4.26 (m, 1H,
CHCp), 4.23e4.19 (m, 8H, 8  CHCp), 3.39e3.35 (m, 2H,
CHCH2CH2NH), 2.25 (br s, 1H, CHOH), 2.14e1.97 (m, 2H,
CHCH2CH2NH). 13C NMR (101 MHz, CDCl3) d ¼ 143.7 (CAr), 142.0
(CAr), 141.7 (CAr), 129.6 (CAr), 129.0 (CAr), 126.9 (CAr), 125.9 (CAr),
124.7 (CAr), 109.8 (CAr), 93.6 (CCp), 68.9 (CHOH), 68.4 (5  CCp), 68.3
(CCp), 68.2 (CCp), 67.0 (CCp), 65.2 (CCp), 41.2 (CHCH2CH2NH), 36.6
(CHCH2CH2NH). IR (ATR, cm1): n ¼ 3300 (NeH) cm1; n ¼ 3200
(OeH) cm1. MS (70eV): m/z (%) 387.0 ([Mþ H]þ).
4.1.3.3. 1-Ferrocenyl-3-(quinolin-5-ylamino)propan-1-ol (6c).
Yellow solid; mp 169 C. Rf ¼ 0.85 (EtOAc/MeOH, 9:1 (v/v)). Yield
98%. 1H NMR (400 MHz, CDCl3) d ¼ 8.85 (dd, J ¼ 4.2, 1.4 Hz, 1H,
CHAr), 8.14 (d, J ¼ 8.5 Hz, 1H, CHAr), 7.55 (dd, J ¼ 8.2, 7.8 Hz, 1H,
CHAr), 7.45 (d, J ¼ 8.2 Hz, 1H, CHAr), 7.30 (dd, J ¼ 8.5, 4.2 Hz, 1H,
CHAr), 6.59 (d, J ¼ 7.8 Hz, 1H, CHAr), 5.24 (s, 1H, CHCH2CH2NH), 4.64
(dd, J ¼ 8.2, 3.8 Hz, 1H, CHOH), 4.29e4.27 (m, 1H, CHCp), 4.24e4.18
(m, 8H, 8  CHCp), 3.50e3.35 (m, 2H, CHCH2CH2NH), 2.46 (br s, 1H,
CHOH), 2.23e2.07 (m, 2H, CHCH2CH2NH). 13C NMR (101 MHz,CDCl3) d¼ 149.9 (CAr),149.2 (CAr), 144.1 (CAr), 130.5 (CAr), 129.1 (CAr),
119.2 (CAr), 118.5 (CAr), 117.9 (CAr), 104.1 (CAr), 93.6 (CCp), 69.9
(CHOH), 68.4 (5  CCp), 68.3 (CCp), 68.2 (CCp), 67.0 (CCp), 65.3 (CCp),
42.2 (CHCH2CH2NH), 36.5 (CHCH2CH2NH). IR (ATR, cm1): n¼ 3420
(NeH) cm1; n ¼ 3363 (OeH) cm1. MS (70eV):m/z (%) 387.0 ([Mþ
H]þ). HRMS (ESI): m/z for C22H22FeN2O [MþH]þ calcd 387.1155,
found 387.1162.
4.1.3.4. 1-Ferrocenyl-3-(quinolin-6-ylamino)propan-1-ol (6d).
Yellow solid; mp 131 C. Rf ¼ 0.32 (EtOAc/MeOH, 9:1 (v/v)). Yield
97%. 1H NMR (400 MHz, CDCl3) d ¼ 8.60 (dd, J ¼ 4.1, 1.4 Hz, 1H,
CHAr), 7.90 (dd, J ¼ 8.2, 1.4 Hz, 1H, CHAr), 7.86 (d, J ¼ 9.0 Hz, 1H,
CHAr), 7.25 (dd, J¼ 8.2, 4.1 Hz,1H, CHAr), 7.08 (dd, J¼ 9.0, 2.6 Hz,1H,
CHAr), 6.68 (d, J ¼ 2.6 Hz, 1H, CHAr), 4.57 (dd, J ¼ 8.2, 4.2 Hz, 1H,
CHOH), 4.42 (br s, 1H, CHCH2CH2NH), 4.27e4.26 (m, 1H, CHCp),
4.22e4.18 (m, 8H, 8  CHCp), 3.38 (t, J ¼ 6.4 Hz, 2H, CHCH2CH2NH),
2.25 (br s, 1H, CHOH), 2.13e1.97 (m, 2H, CHCH2CH2NH). 13C NMR
(101 MHz, CDCl3) d¼ 146.3 (CAr), 146.0 (CAr), 143.2 (CAr), 133.8 (CAr),
130.20 (CAr), 130.17 (CAr), 121.6 (CAr), 121.3 (CAr), 102.8 (CAr), 93.6
(CCp), 68.9 (CHOH), 68.4 (5  CCp), 68.2 (CCp), 68.1 (CCp), 67.0 (CCp),
65.3 (CCp), 41.4 (CHCH2CH2NH), 36.8 (CHCH2CH2NH). IR (ATR,
cm1): n¼ 3404 (NeH) cm1; n¼ 3212 (OeH) cm1. MS (70eV):m/z
(%) 387.0 ([Mþ H]þ).
4.1.3.5. 1-Ferrocenyl-3-(quinolin-8-ylamino)propan-1-ol (6e).
Yellow solid; mp 98 C. Rf ¼ 0.48 (Тоluene/EtOAc, 9:1 (v/v)). Yield
95%. 1H NMR (400 MHz, CDCl3) d ¼ 8.71 (dd, J ¼ 4.2, 1.7 Hz, 1H,
CHAr), 8.04 (dd, J¼ 8.3, 1.7 Hz, 1H, CHAr), 7.37 (dd, J¼ 8.0, 7.8 Hz, 1H,
CHAr), 7.35 (dd, J¼ 8.3, 4.2 Hz,1H, CHAr), 7.03 (dd, J¼ 8.0, 0.8 Hz,1H,
CHAr), 6.69 (dd, J ¼ 7.8, 0.8 Hz, 1H, CHAr), 6.33 (br s, 1H,
CHCH2CH2NH), 4.59 (dd, J ¼ 8.1, 4.1 Hz, 1H, CHOH), 4.27e4.26 (m,
1H, CHCp), 4.21e4.20 (m, 1H, CHCp), 4.18e4.15 (m, 7H, 7  CHCp),
3.48 (t, J ¼ 6.6 Hz, 2H, CHCH2CH2NH), 2.21e2.05 (m, 3H, CHOH and
CHCH2CH2NH). 13C NMR (101 MHz, CDCl3) d ¼ 146.9 (CAr), 144.9
(CAr), 138.3 (CAr), 136.0 (CAr), 128.7 (CAr), 127.9 (CAr), 121.4 (CAr),
113.8 (CAr), 104.7 (CAr), 93.8 (CCp), 68.4 (5  CCp), 68.2 (CHOH), 68.1
(CCp), 68.0 (CCp), 67.0 (CCp), 65.6 (CCp), 40.7 (CHCH2CH2NH), 37.3
(CHCH2CH2NH). IR (ATR, cm1): n ¼ 3410 (NeH) cm1; n ¼ 3302
(OeH) cm1. MS (70eV): m/z (%) 387.0 ([Mþ H]þ).
4.1.4. General procedure for the synthesis of N-(3-ferrocenylprop-2-
en-1-yl)-2,2,2-trifluoro-N-(quinolinyl)acetamides (7a-e)
Triethylamine (1.5 mmol) and trifluoroacetic anhydride
(1.5 mmol) were added dropwise to a cooled solution (an ice bath)
of the corresponding 1,3-aminoalcohol 6a-e (1 mmol) in 5ml of dry
tetrahydrofuran (THF). The reaction mixture was stirred for 16 h
(first 5 h in an ice bath) under nitrogen atmosphere. After that, THF
was evaporated, the mixture was neutralized with a saturated so-
lution of NaHCO3 (litmus paper) and extracted with CH2Cl2 (two
20 ml portions). The combined organic layers were washed with
water, brine and dried over anh. Na2SO4. After filtration, the solvent
was evaporated, and the crude product 7a-e was purified by col-
umn chromatography (SiO2).
4.1.4.1. (E)-N-(3-Ferrocenylprop-2-en-1-yl)-2,2,2-trifluoro-N-(quino-
lin-4-yl)acetamide (7a). Dark red oil; Rf ¼ 0.67 (Petroleum ether/
EtOAc, 7:3 (v/v)). Yield 80%. 1H NMR (400 MHz, CDCl3) d ¼ 8.99 (d,
J¼ 4.5 Hz,1H, CHAr), 8.24 (d, J¼ 8.5 Hz,1H, CHAr), 7.88e7.81 (m, 2H,
2 CHAr), 7.70 (ddd, J¼ 8.8, 7.0, 1.0 Hz, 1H, CHAr), 7.24 (d, J¼ 4.5 Hz,
1H, CHAr), 6.14 (d, J ¼ 15.5 Hz, 1H, CH]CHCH2), 5.83 (ddd, J ¼ 15.5,
8.4, 6.2 Hz, 1H, CH]CHCH2), 4.97 (ddd, J ¼ 14.0, 6.2, 0.9 Hz, 1H,
CH]CH(HCH)), 4.28e4.18 (m, 4H, 4  CHCp), 3.99 (s, 5H, 5  CHCp),
A. Minic et al. / European Journal of Medicinal Chemistry 187 (2020) 111963 113.92 (dd, J ¼ 14.0, 8.4 Hz, 1H, CH]CH(HCH)). 13C NMR (101 MHz,
CDCl3) d ¼ 156.5 (NC]OCF3)*, 150.3 (CAr), 149.9 (CAr), 143.1 (CAr),
134.9 (CH]CHCH2), 130.5 (CAr), 130.4 (CAr), 128.3 (CAr), 125.2 (CAr),
122.2 (CAr), 121.4 (CAr), 117.6 (CH]CHCH2), 114.6 (CF3)*, 81.3 (CCp),
69.2 (2  CCp), 69.1 (5  CCp), 67.2 (CCp), 66.8 (CCp), 53.8 (CH2). 19F
NMR (376 MHz, CDCl3) d ¼ 75.6 (CF3). IR (ATR, cm1): n ¼ 1697
(C]O) cm1. MS (70eV): m/z (%) 465.0 ([Mþ H]þ).4.1.4.2. (E)-N-(3-Ferrocenylprop-2-en-1-yl)-2,2,2-trifluoro-N-(qui-
nolin-3-yl)acetamide (7b). Dark red solid; mp 88 C. Rf ¼ 0.62
(Petroleum ether/EtOAc, 9:1 (v/v)). Yield 84%. 1H NMR (400 MHz,
CDCl3) d¼ 8.80 (d, J¼ 2.0 Hz,1H, CHAr), 8.17 (d, J¼ 8.4 Hz,1H, CHAr),
8.03 (d, J¼ 2.0 Hz,1H, CHAr), 7.87 (d, J¼ 8.2 Hz, 1H, CHAr), 7.81 (ddd,
J ¼ 8.4, 7.0, 1.3 Hz, 1H, CHAr), 7.63 (ddd, J ¼ 8.2, 7.0, 1.1 Hz, 1H, CHAr),
6.20 (d, J ¼ 15.5 Hz, 1H, CH]CHCH2), 5.82 (ddd, J ¼ 15.5, 7.1, 7.1 Hz,
1H, CH]CHCH2), 4.46 (d, J¼ 7.1 Hz, 2H, CH]CHCH2), 4.27e4.25 (m,
2H, 2  CHCp), 4.21e4.20 (m, 2H, 2  CHCp), 3.98 (s, 5H, 5  CHCp).
13C NMR (101 MHz, CDCl3) d ¼ 156.7 (q, J ¼ 36.0 Hz, NC]OCF3),
150.0 (CAr), 147.6 (CAr), 135.2 (CAr), 134.7 (CH]CHCH2), 132.2 (CAr),
130.9 (CAr), 129.6 (CAr), 128.1 (CAr), 127.9 (CAr), 127.2 (CAr), 117.7
(CH]CHCH2), 116.2 (q, J¼ 288.5 Hz, CF3), 81.4 (CCp), 69.12 (2 CCp),
69.1 (5  CCp), 67.0 (2  CCp), 54.5 (C, CH2). 19F NMR (376 MHz,
CDCl3) d ¼ 67.1 (CF3). IR (ATR, cm1): n ¼ 1693 (C]O) cm1. MS
(70eV): m/z (%) 465.0 ([Mþ H]þ). HRMS (ESI): m/z for
C24H19F3FeN2O [MþH]þ calcd 465.0872, found 465.0887.4.1.4.3. (E)-N-(3-Ferrocenylprop-2-en-1-yl)-2,2,2-trifluoro-N-(qui-
nolin-5-yl)acetamide (7c). Dark red oil; Rf ¼ 0.62 (Petroleum ether/
EtOAc, 7:3 (v/v)). Yield 78%. 1H NMR (400 MHz, CDCl3) d ¼ 9.03 (d,
J¼ 3.9 Hz,1H, CHAr), 8.22 (d, J¼ 8.6 Hz,1H, CHAr), 8.18 (d, J¼ 8.4 Hz,
1H, CHAr), 7.75 (dd, J¼ 8.4, 7.4 Hz,1H, CHAr), 7.55 (dd, J¼ 8.6, 3.9 Hz,
1H, CHAr), 7.43 (d, J¼ 7.4 Hz, 1H, CHAr), 6.12 (d, J¼ 15.5 Hz,1H, CH]
CHCH2), 5.84 (ddd, J ¼ 15.5, 8.2, 6.3 Hz, 1H, CH]CHCH2), 4.92 (ddd,
J ¼ 13.9, 6.3, 0.9 Hz, 1H, CH]CH(HCH)), 4.30e4.20 (m, 4H,
4  CHCp), 4.01 (s, 5H, 5  CHCp), 3.91 (dd, J ¼ 13.9, 8.2 Hz, 1H, CH,
CH]CH(HCH)). 13C NMR (101 MHz, CDCl3) d ¼ 157.4 (q, J ¼ 36.1 Hz,
NC]OCF3), 156.5 (CAr), 151.2 (CAr), 148.9 (CAr), 134.6 (CH]CHCH2),
131.5 (CAr), 130.8 (CAr), 128.5 (CAr), 127.9 (CAr), 125.7 (CAr), 122.4
(CAr), 118.1 (CH]CHCH2), 116.2 (q, J ¼ 288.6 Hz, CF3), 81.6 (CCp),
69.22 (5  CCp), 69.20 (2  CCp), 67.04 (CCp), 67.00 (CCp), 53.4 (CH2).
19F NMR (376MHz, CDCl3) d¼68.3 (CF3). IR (ATR, cm1): n¼ 1593
(C]O) cm1. MS (70eV): m/z (%) 465.0 ([Mþ H]þ).4.1.4.4. (E)-N-(3-Ferrocenylprop-2-en-1-yl)-2,2,2-trifluoro-N-(qui-
nolin-6-yl)acetamide (7d). Dark red solid; mp ¼ 83 C. Rf ¼ 0.71
(Petroleum ether/EtOAc, 7:3 (v/v)). Yield 87%. 1H NMR (400 MHz,
CDCl3) d¼ 8.99 (d, J¼ 3.9 Hz,1H, CHAr), 8.20 (d, J¼ 8.7 Hz,1H, CHAr),
8.18 (d, J ¼ 8.1 Hz, 1H, CHAr), 7.69 (s, 1H, CHAr), 7.57 (dd, J ¼ 8.7,
1.7 Hz, 1H, CHAr), 7.47 (dd, J ¼ 8.1, 3.9 Hz, 1H, CHAr), 6.20 (d,
J ¼ 15.6 Hz, 1H, CH]CHCH2), 5.88e5.81 (m, 1H, CH]CHCH2),
4.50e4.38 (m, 2H, CH]CHCH2), 4.29e4.26 (m, 2H, 2  CHCp),
4.22e4.19 (m, 2H, 2  CHCp), 3.99 (s, 5H, 5  CHCp). 13C NMR
(101 MHz, CDCl3) d ¼ 156.6 (q, J ¼ 35.6 Hz, NC]OCF3), 151.8 (CAr),
147.7 (CAr), 136.8 (CAr), 136.3 (CAr), 134.0 (CH]CHCH2), 131.3 (CAr),
129.5 (CAr), 128.0 (CAr), 127.5 (CAr), 122.1 (CAr), 118.3 (CH]CHCH2),
114.9 (q, J ¼ 288.5 Hz, CF3), 81.5 (CCp), 69.08 (5  CCp), 69.06 (CCp),
67.0 (2 Cp), 54.4 (CH2). 19F NMR (376MHz, CDCl3) d¼67.1 (CF3).
IR (ATR, cm1): n ¼ 1693 (C]O) cm1. MS (70eV): m/z (%) 465.0
([Mþ H]þ). HRMS (ESI): m/z for C24H19F3FeN2O [MþH]þ calcd
465.0872, found 465.0876.* Coupling between C and F not visible.4.1.4.5. (E)-N-(3-Ferrocenylprop-2-en-1-yl)-2,2,2-trifluoro-N-(qui-
nolin-8-yl)acetamide (7e). Dark red oil; Rf ¼ 0.81 (Petroleum ether/
EtOAc, 7:3 (v/v)). Yield 81%. 1H NMR (400 MHz, CDCl3) d ¼ 9.03 (dd,
J¼ 4.2, 1.7 Hz, 1H, CHAr), 8.25 (dd, J¼ 8.3, 1.7 Hz, 1H, CHAr), 7.92 (dd,
J ¼ 7.7, 1.9 Hz, 1H, CHAr), 7.64e7.56 (m, 2H, 2  CHAr), 7.53 (dd,
J ¼ 8.3, 4.2 Hz, 1H, CHAr), 6.07 (d, J ¼ 15.6 Hz, 1H, CH]CHCH2), 5.87
(ddd, J¼ 15.6, 7.7, 6.0 Hz, 1H, CH]CHCH2), 5.06 (dd, J¼ 14.1, 6.0 Hz,
1H, CH]CH(HCH)), 4.25e4.15 (m, 5H, CH]CH(HCH) and 4 CHCp),
3.92 (s, 5H, 5  CHCp). 13C NMR (101 MHz, CDCl3) d ¼ 157.6 (q,
J ¼ 35.5 Hz, NC]OCF3), 151.1 (CAr), 144.5 (CAr), 136.3 (CAr), 136.1
(CAr), 132.9 (CH]CHCH2), 130.0 (CAr), 129.5 (CAr), 129.1 (CAr), 125.8
(CAr), 122.1 (CAr), 119.6 (CH]CHCH2), 116.4 (q, J ¼ 288.6 Hz, CF3),
81.9 (CCp), 69.1 (5  CCp), 68.8 (2  CCp), 66.9 (CCp), 66.8 (CCp), 53.6
(CH2). 19F NMR (376 MHz, CDCl3) d ¼ 68.4 (CF3). IR (ATR, cm1):
n ¼ 1689 (C]O) cm1. MS (70eV): m/z (%) 465.0 ([Mþ H]þ).
4.1.5. General procedure for the synthesis of ferrocene-containing
heterotricycles (8a-e) [21]
A mixture of the corresponding ferrocene-containing 1,3-amino
alcohol 6a-e (1 mmol) and glacial acetic acid (0.5 ml) was ultra-
sonicated in an ultrasonic cleaner for 2 h. The reaction mixture was
neutralized with NaHCO3 (litmus paper) and extracted with CH2Cl2
(two 20 ml portions). The combined organic layers were washed
with water and dried over anh. Na2SO4. After filtration, the solvent
was evaporated and the crude product (8a-e) was purified by col-
umn chromatography (SiO2).
4.1.5.1. 4-Ferrocenyl-1,2,3,4-tetrahydrobenzo[h] [1,6]naphthyridine
(8a). No analytically pure sample could be obtained for compound
8a. Due to the presence of impurities, no accurate 1H and 13C NMR
assignments could thus be provided for this structure.
Yellow solid; mp 196 C. Rf ¼ 0.48 (EtOAc/MeOH, 9:1 (v/v)).
Yield 85%. IR (ATR, cm1): n¼ 2852 (NeH) cm1. MS (70eV):m/z (%)
369.0 ([Mþ H]þ).
4.1.5.2. 1-Ferrocenyl-1,2,3,4-tetrahydrobenzo[f] [1,7]naphthyridine
(8b). Yellow solid; mp 203 C. Rf ¼ 0.34 (Petroleum ether/EtOAc,
7:3 (v/v)). Yield 95%. 1H NMR (400 MHz, CDCl3) d ¼ 8.31 (s, 1H,
CHAr), 8.07 (d, J ¼ 8.4, 1.2 Hz, 1H, CHAr), 7.94 (dd, J ¼ 8.3, 1.2 Hz, 1H,
CHAr), 7.50 (ddd, J ¼ 8.4, 6.9, 1.2 Hz, 1H, CHAr), 7.39 (ddd, J¼ 8.3, 6.9,
1.2 Hz, 1H, CHAr), 4.53 (s, 1H, CHCH2CH2NH), 4.17 (s, 1H,
CHCH2CH2NH), 4.12e4.10 (m, 1H, CHCp), 4.10e4.07 (m, 6H,
6  CHCp), 4.03e4.01 (m, 1H, CHCp), 3.80e3.77 (m, 1H, CHCp),
3.46e3.33 (m, 2H, CHCH2CH2NH), 2.30e2.25 (m, 1H, CH(HCH)
CH2NH), 2.05e1.96 (m, 1H, CH(HCH)CH2NH). 13C NMR (101 MHz,
CDCl3) d¼ 142.9 (CAr), 142.1 (CAr), 136.6 (CAr), 129.8 (CAr), 128.1 (CAr),
126.3 (CAr), 124.1 (CAr), 122.4 (CAr), 121.0 (CAr), 93.9 (CCp), 69.1 (CCp),
68.9 (5 CCp), 67.3 (CCp), 66.7 (CCp), 66.6 (CCp), 37.1 (CHCH2CH2NH),
30.1 (CHCH2CH2NH), 27.3 (CHCH2CH2NH). IR (ATR, cm1): n ¼ 2922
(NeH) cm1. MS (70eV): m/z (%) 369.0 ([Mþ H]þ). HRMS (ESI): m/z
for C22H20FeN2 [MþH]þ calcd 369.1049, found 369.1047.
4.1.5.3. 4-Ferrocenyl-1,2,3,4-tetrahydro-1,7-phenanthroline (8c).
Yellow solid; mp 200 C. Rf ¼ 0.71 (EtOAc/MeOH, 9:1 (v/v)). Yield
98%. 1H NMR (400 MHz, CDCl3) d ¼ 8.83 (dd, J ¼ 4.2, 1.2 Hz, 1H,
CHAr), 8.06 (d, J ¼ 8.5 Hz, 1H, CHAr), 7.57 (d, J ¼ 8.6 Hz, 1H, CHAr),
7.43 (d, J¼ 8.6 Hz, 1H, CHAr), 7.29 (dd, J¼ 8.5, 4.2 Hz, 1H, CHAr), 4.53
(s, 1H, CHCH2CH2NH), 4.19 (s, 5H, 5  CHCp), 4.16e4.13 (m, 2H,
2  CHCp), 4.08e4.05 (m, 1H, CHCp), 4.03 (t, J ¼ 4.8 Hz, 1H,
CHCH2CH2NH), 3.79 (s, 1H, CHCp), 3.47e3.40 (m, 1H, CHCH2(HCH)
NH), 3.37e3.28 (m, 1H, CHCH2(HCH)NH), 2.25e2.24 (m, 1H,
CH(HCH)CH2NH), 2.11e2.04 (m, 1H, CH(HCH)CH2NH). 13C NMR
(101MHz, CDCl3) d¼ 149.5 (CAr), 148.3 (CAr), 138.6 (CAr), 132.4 (CAr),
128.5 (CAr), 119.2 (CAr), 118.0 (CAr), 117.8 (CAr), 117.1 (CAr), 94.3 (CCp),
69.8 (CCp), 68.8 (5  CCp), 67.9 (CCp), 66.7 (CCp), 65.8 (CCp), 39.0
A. Minic et al. / European Journal of Medicinal Chemistry 187 (2020) 11196312(CHCH2CH2NH), 36.4 (CHCH2CH2NH), 29.5 (CHCH2CH2NH). IR (ATR,
cm1): n ¼ 2916 (NeH) cm1. MS (70eV): m/z (%) 369.0 ([Mþ H]þ).4.1.5.4. 1-Ferrocenyl-1,2,3,4-tetrahydro-4,7-phenanthroline (8d).
Yellow solid; mp 180 C. Rf ¼ 0.83 (EtOAc/MeOH, 9:1 (v/v)). Yield
95%. 1H NMR (400 MHz, CDCl3) d ¼ 8.60 (dd, J ¼ 4.2, 1.4 Hz, 1H,
CHAr), 8.40 (d, J ¼ 8.5 Hz, 1H, CHAr), 7.77 (d, J ¼ 9.0 Hz, 1H, CHAr),
7.34 (dd, J¼ 8.5, 4.2 Hz, 1H, CHAr), 6.97 (d, J¼ 9.0 Hz, 1H, CHAr), 4.47
(t, J ¼ 2.8 Hz, 1H, CHCH2CH2NH), 4.15 (br s, 1H, CHCH2CH2NH), 4.08
(s, 7H, 7 CHCp), 4.02e4.00 (m, 1H, CHCp), 3.76e3.74 (m, 1H, CHCp),
3.47e3.40 (m, 1H, CHCH2(HCH)NH), 3.38e3.30 (m, 1H,
CHCH2(HCH)NH), 2.31e2.22 (m, 1H, CH(HCH)CH2NH), 2.04 (m, 1H,
CH(HCH)CH2NH). 13C NMR (101 MHz, CDCl3) d ¼ 145.1 (CAr), 143.2
(CAr), 140.9 (CAr), 130.3 (CAr), 129.0 (CAr), 128.5 (CAr), 121.5 (CAr),
120.6 (CAr), 112.7 (CAr), 95.0 (CCp), 69.1 (CCp), 68.8 (5  CCp), 67.2
(CCp), 66.65 (CCp), 66.57 (CCp), 37.4 (CHCH2CH2NH), 30.2
(CHCH2CH2NH), 27.8 (CHCH2CH2NH). IR (ATR, cm1): n ¼ 2926
(NeH) cm1. MS (70eV): m/z (%) 369.0 ([Mþ H]þ).4.1.5.5. 4-Ferrocenyl-1,2,3,4-tetrahydro-1,10-phenanthroline (8e).
Yellow solid; mp 159 C. Rf ¼ 0.33 (Petroleum ether/EtOAc, 7:3 (v/
v)). Yield 97%. 1H NMR (400MHz, CDCl3) d¼ 8.68 (dd, J¼ 4.2,1.7 Hz,
1H, CHAr), 8.02 (dd, J ¼ 8.3, 1.7 Hz, 1H, CHAr), 7.35 (d, J ¼ 8.4 Hz,
CHAr), 7.31 (dd, J ¼ 8.3, 4.2 Hz, 1H, CHAr), 6.99 (d, J ¼ 8.4 Hz, 1H,
CHAr), 6.06 (s, 1H, CHCH2CH2NH), 4.19 (s, 5H, 5  CHCp), 4.15e4.14
(m, 2H, 2  CHCp), 4.08e4.05 (m, 1H, CHCp), 4.02 (t, J ¼ 5.0 Hz, 1H,
CHCH2CH2NH), 3.86e3.84 (m, 1H, CHCp), 3.54e3.46 (m, 1H,
CHCH2(HCH)NH), 3.42e3.34 (m, 1H, CHCH2(HCH)NH), 2.34e2.25
(m, 1H, CH(HCH)CH2NH), 2.14e2.05 (m, 1H, CH(HCH)CH2NH). 13C
NMR (101 MHz, CDCl3) d ¼ 146.8 (CAr), 140.1 (CAr), 137.5 (CAr), 135.8
(CAr), 129.2 (CAr), 127.6 (CAr), 120.8 (CAr), 118.4 (CAr), 112.3 (CAr), 94.5
(CCp), 69.8 (5 CCp), 68.7 (CCp), 67.8 (CCp), 66.6 (CCp), 65.9 (CCp), 38.4
(CHCH2CH2NH), 36.4 (CHCH2CH2NH), 29.5 (CHCH2CH2NH). IR (ATR,
cm1): n ¼ 2922 (NeH) cm1. MS (70eV): m/z (%) 369.0 ([Mþ H]þ).
HRMS (ESI): m/z for C22H20FeN2 [MþH]þ calcd 369.1049, found
369.1044.Table 9
Crystallographic data and structure refinement for 7d and 8e.
Compound 7d
Empirical formula C25H23F3FeN2O2
Formula weight 496.30
Temperature/K 100.0(1)
Crystal system Triclinic
Space group P-1
a/Å 10.9525(3)
b/Å 11.6584(4)
c/Å 18.0342(5)
a/ 105.075(3)
b/ 98.806(3)
g/ 90.119(3)
Volume/Å3 2195.19(12)
Z 4
Рcalcg/cm3 1.502
m/mm1 5.960
F(000) 1024.0
Crystal size/mm3 0.161  0.129  0.061
Radiation CuKa (l ¼ 1.54184)
2Q range for data collection/ 7.862 to 150.992
Index ranges 13  h  13, 14  k  14,
Reflections collected 41945
Independent reflections 8886 [Rint ¼ 0.0669, Rsigma ¼
Data/restraints/parameters 8886/0/599
Goodness-of-fit on F2 1.020
Final R indexes [I  2s (I)] R1 ¼ 0.0422, wR2 ¼ 0.1009
Final R indexes [all data] R1 ¼ 0.0572, wR2 ¼ 0.1101
Largest diff. peak/hole/e Å3 0.99/-0.374.1.6. X-ray data collection and structure refinement for compounds
7d and 8e
Single-crystal X-ray intensity data for compounds
C25H23F3FeN2O2 (7d) and C22H20FeN2 (8e) were collected on a
Rigaku Oxford Diffraction SuperNova Dual Source (Cu at zero)
diffractometer equipped with an Atlas CCD detector using u scans
and CuKa (l ¼ 1.54184 Å) radiation. The crystals were kept at
100.0(1) K during data collection. Using Olex2 [35], the structures
were solved by direct methods using SHELXS and refined on F2 by
full-matrix least-squares using SHELXL [36,37]. Non-hydrogen
atoms were anisotropically refined and the hydrogen atoms in
the ridingmode and isotropic temperature factors fixed at 1.2 times
U(eq) of the parent atoms (1.5 times for methyl and hydroxyl
groups). NeH and OeH hydrogen atoms were located, when
possible, from a difference Fourier electron density map. Crystal-
lographic details for structure analysis of compounds 7d and 8e are
summarized in Table 9. (for more data see ESI).
4.2. Bioactivity evaluation methods
4.2.1. In vitro antimalarial assay
The test samples were prepared to a 20 mg/ml stock solution in
100% DMSO. Stock solutions were stored at 20 C. Further di-
lutions were prepared in complete medium on the day of the
experiment. Samples were tested as a suspension if not completely
dissolved. Chloroquine (CQ) was used as the reference drugs. A full
dose-response was performed to determine the concentration
inhibiting 50% of parasite growth (IC50evalue). Test samples were
tested at a starting concentration of 10 mg/ml (or 1 mg/ml), which
was then serially diluted 2-fold in complete medium to give 10
concentrations; with the lowest concentration being 20 ng/ml (or
2 ng/ml). The same dilution techniquewas used for all samples. The
highest concentration of solvent to which the parasites were
exposed to had no measurable effect on the parasite viability (data
not shown). The 50% inhibitory concentration (IC50) values were
obtained from full dose-response curves, using a non-linear dose-
response curve fitting analysis via GraphPad Prism v.4 software.8e
C22H20FeN2
368.25
100.0(1)
Triclinic
P-1
7.2660(4)
9.2877(5)
13.5927(7)
73.730(5)
79.029(4)
68.520(5)
815.44(8)
2
1.500
7.441
384.0
0.266  0.162  0.114
CuKa (l ¼ 1.54184)
6.808 to 150.658
22  l  22 9  h  9, 11  k  10, 17  l  17
15490
0.0527] 3315 [Rint ¼ 0.0463, Rsigma ¼ 0.0304]
3315/0/229
1.035
R1 ¼ 0.0289, wR2 ¼ 0.0772
R1 ¼ 0.0302, wR2 ¼ 0.0786
0.32/-0.54
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The same stock solutions prepared for antiplasmodium testing
was used for cytotoxicity testing. Test compounds were stored
at 20 C until use. Dilutions were prepared on the day of the
experiment. Emetine was used as the reference drug in all experi-
ments. The initial concentration of emetine was 100 mg/ml, which
was serially diluted in complete medium with 10-fold dilutions to
give 6 concentrations, the lowest being 0.001 mg/ml. The same
dilution technique was applied for all test samples. The highest
concentration of solvent to which the cells were exposed to had no
measurable effect on the cell viability (data not shown). The 50%
inhibitory concentration (IC50) values were obtained from full dose-
response curves, using a non-linear dose-response curve fitting
analysis via GraphPad Prism v.4 software.
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